Introduction
============

Ewing sarcoma (ES) is an aggressive sarcoma of bone and/or soft tissue with a peak incidence in children and young adults, it is the third most common malignant primary bone tumor, following osteosarcoma and chondrosarcoma ([@b1-mmr-18-05-4229],[@b2-mmr-18-05-4229]). Over the past decades, efforts have been made to maximize the chance of cure and pathogenesis of ES through collaboration among clinicians, pathologists, and biologists ([@b3-mmr-18-05-4229]). The overall survival (OS) for ES patients with localized disease is \~70%, but the OS of patients with metastatic disease is only \~30% ([@b4-mmr-18-05-4229]). Further efforts should be made to improve these outcomes, especially for patients with metastatic and recurrent ES.

Efforts of researchers and clinicians have advanced the understanding of ES oncogenesis and the genetic predisposition for developing ES ([@b5-mmr-18-05-4229]). ES is defined by a balanced translocation that involves the Ewing sarcoma breakpoint region 1 (*EWSR1*) gene located on chromosome 22, and a member of the E26 transformation-specific (*ETS*) family of transcription factors that mainly contain the friend leukemia integration 1 (*FLI1*) and EST-related gene (*ERG) genes* ([@b6-mmr-18-05-4229]). Two types of translocation are generally observed on the molecular analysis of ES samples. The first most common type, accounting for 85% of the translocations, occurs when the *EWSR1* fuse to the *FLI1* gene which is located on chromosome 11, resulting in an *EWSR1-FLI1* fusion gene ([@b7-mmr-18-05-4229]). The second most common translocation in ES, occurs when the *EWS* gene fuses to another member of the *ETS* transcription factor family, *ERG*, located on chromosome 21, resulting in an *EWSR1-ERG* fusion gene ([@b8-mmr-18-05-4229],[@b9-mmr-18-05-4229]). Besides *FLI1* and *ERG*, other members of the *ETS* transcription factor family that can act as partners for *EWSR1* are *ETV, ETV4*, and *FEV* ([@b10-mmr-18-05-4229]--[@b12-mmr-18-05-4229]). These fusion oncoproteins might serve as potential diagnostic markers and therapeutic targets for ES. However, several reports demonstrated that in addition to the expression of *FLI1* in ES, it can also be detected in other neoplasms including lymphoblastic lymphomas, Merkel cell carcinoma, desmoplastic small round cell tumor, and synovial sarcoma, endothelial cells and lymphocytes also normally express *FLI1* ([@b13-mmr-18-05-4229]--[@b15-mmr-18-05-4229]). To date, no specific and accurate molecular markers have been established for the early diagnosis and treatment of ES, and therefore identification of new molecular markers is urgently needed.

In the present study, a meta-analysis of several ES transcriptome datasets from the Gene Expression Omnibus (GEO) was performed. Differential expressed genes (DEGs) in ES compared with normal tissues were identified and subjected to network analysis. A Kaplan-Meier analysis of core genes networks was performed and several survival-associated genes were identified that could act as potential markers for the prognosis of patients with ES.

Materials and methods
=====================

### Datasets

With the keyword of 'Ewing Sarcoma' and restriction of organism='Homo sapiens', platform='GPL570' and attribute='Tissue', a total of three datasets with the accession number of GSE34620 ([@b5-mmr-18-05-4229]), GSE17618 ([@b16-mmr-18-05-4229]) and GSE17674 ([@b16-mmr-18-05-4229]) were obtained from the GEO ([www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)). There are 117 ES tissue samples in GSE34620 and 44 ES tissue samples in GSE17618 and without normal samples aside from the 18 in GSE17674. For GSE17674, a total of 44 ES tissue samples and 18 normal skeletal muscle samples were included. [Table I](#tI-mmr-18-05-4229){ref-type="table"} demonstrates detailed information of datasets used in the present study.

### Microarray preprocessing

The raw datasets were firstly normalized prior to differential expression analysis. In brief, the CEL files were imported into R ([www.r-project.org/](www.r-project.org/)), a free access statistics software, to conduct batch normalization with the *sva* package ([@b17-mmr-18-05-4229]). Probe level expression values were transformed to gene level based on the microarray annotation file. For genes corresponding to multi probes, the mean expression value was used.

### Differential expression analysis

The *limma* package ([@b18-mmr-18-05-4229]) was used for the identification of genes with aberrant expression profiles in ES compared with normal tissues. The t-test and FDR correction were used to test significance of expression differences between ES and normal tissues, and only those genes with adjusted P\<0.05 and \|log2Fold Change\|\>1 (fold change \>2 or \<0.5) were considered with a significantly differential expression.

### Functional enrichment analysis

To explore functions involved in differential expression genes (DEGs) in ES samples, the Database for Annotation, Visualization and Integrated Discovery (DAVID, [david.ncifcrf.gov/](david.ncifcrf.gov/)) ([@b19-mmr-18-05-4229]) was used for the functional enrichment analysis, and Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genome (KEGG) pathways with P-value \<0.05 were screened out. In addition, to interpret associations among those functions, the enrichmentMap plug-in ([@b20-mmr-18-05-4229]) of Cytoscape software ([@b21-mmr-18-05-4229]) was used to perform crosstalk analysis of Biological Process (BP) terms.

### Network analysis

By combining the network deposited in Protein Interaction Network Analysis (PINA, [cbg.garvan.unsw.edu.au/pina/](cbg.garvan.unsw.edu.au/pina/)) ([@b22-mmr-18-05-4229]) and Menche\'s study ([@b23-mmr-18-05-4229]), interaction pairs among DEGs were screened. Additionally, the MCODE plug-in of Cytoscape software was used to conducted modular analysis of the whole network.

### Kaplan-Meier analysis

Hub network genes (genes with high degree) should serve an important role in ES progression for the high number genes directly interacting with them. In the present study, a Kaplan-Meier analysis for hub network genes was conducted based on another ES-associated dataset downloaded from The Cancer Genome Atlas (TCGA; [cancergenome.nih.gov/](cancergenome.nih.gov/)) to identify genes significantly associated with ES overall survival (OS).

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated from ES cell lines A673 and normal mesenchymal stem cells (MSC, from Cyagen Biosciences, Guangzhou, China) using an RNeasy^®^ Mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer\'s protocol. First-strand cDNA was synthesized from 11 µg of total RNA using the Transcript or First Strand cDNA Synthesis kit (Roche Diagnostics, GmbH, Mannheim, Germany) according to the manufacturer\'s protocol. RT-qPCR reactions were performed on an ABI 7500 real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) using the following procedure: 95°C for 10 min, followed by 40 cycles of 95°C for 30 sec and 60°C for 1 min. Primers used for *glycogen phosphorylase (PYGM)* are (5′-\>3′): Forward primer, 5-TTTCACACTCGTAAAGGACCGCAAT-3, and reverse primer, 5-TGTTCTGTAGCGTCCGTCCCATATA-3. Primers used for *myocyte-specific enhancer factor (MEF)2C* are (5′-\>3′): Forward primer, 5-TGGGTTGATGAAGAAGGCTTATGAG-3, and reverse primer, 5-TAAGGCCCTTCTTTCTCAACGTCTC-3. Primers used for Tripartite Motif Containing (*TRIM)63* are (5′-\>3′): Forward primer, 5-AAGCCAGTGGTCATCTTGCCGT-3, and reverse primer, 5-CGTACACTCCGTGACGATCCATGA-3. Primers used for BUB1B, budding uninhibited by benzimidazoses (*BUB1B*) are (5′-\>3′): Forward primer, 5-GTATAAACCACATCCTAAGCACCAG-3, and reverse primer, 5-CTCTGCACTGGTCAATAGCTCGGCT-3. Primers used for Ras GTPase-activating protein (*RACGAP)1* are (5′-\>3′): Forward primer, 5-TGGCAAATTATCTCTGAAGTGTCGA-3, and reverse primer, 5-CTCTTTGCTCAATCTCATTTACACA-3. GAPDH was used as an internal control. The 2^−ΔΔCq^ method was used for data analysis ([@b24-mmr-18-05-4229]).

Results
=======

### DEGs

Through the thresholds of adjusted P\<0.05 and \|log2Fold Change\|\>1, a total of 1,470 DEGs were obtained in ES samples compared to normal samples with 984 upregulated and 486 downregulated genes. [Fig. 1A](#f1-mmr-18-05-4229){ref-type="fig"} shows the heatmap of the top 100 most significant genes with green and red color representing low and high expression levels, respectively. [Fig. 1B](#f1-mmr-18-05-4229){ref-type="fig"} shows the distribution of DEGs with the green and red dots indicating down- and upregulated genes and the black dots indicating the non-differentially expressed genes.

### Functional enrichment analysis

The significantly enriched KEGG pathways of down- and upregulated genes were separately analyzed. As a result, a total of 25 KEGG pathways that significantly associated with substance metabolism, such as insulin signaling pathway, 2-Oxocarboxylic acid metabolism were significantly enriched in downregulated genes ([Fig. 2A](#f2-mmr-18-05-4229){ref-type="fig"}). However, upregulated genes were demonstrated to be involved in 17 KEGG pathways associated with cancer development and cell activity, including the p53 signaling pathway, and cell cycle ([Fig. 2B](#f2-mmr-18-05-4229){ref-type="fig"}).

GO terms enrichment analysis for DEGs was performed and 173 significantly enriched GO terms were identified. For BP terms, their association through the enrichment Map plug-in of Cytoscape software was explored. As a result, five clusters were obtained, which were associated with muscle contraction, cell division, extracellular matrix organization, response to stimuli and metabolism, respectively ([Fig. 2C](#f2-mmr-18-05-4229){ref-type="fig"}).

### Network analysis

Combined analysis of network of PINA and a study by Menche *et al* ([@b23-mmr-18-05-4229]) identified 13,259 interaction pairs among the 1,470 DEGs. Modular analysis obtained a total of six network modules contained five upregulated and one downregulated module as shown in [Fig. 3](#f3-mmr-18-05-4229){ref-type="fig"}. For interpretation of the biological processes of every module, KEGG pathway analysis for module genes through KOBAS online tool ([kobas.cbi.pku.edu.cn/](kobas.cbi.pku.edu.cn/)) was conducted ([@b25-mmr-18-05-4229]). As a result, besides cancer-associated pathways, KEGG pathways associated with nervous system diseases, such as Parkinson\'s disease, Huntington\'s disease, were also significantly enriched in several network modules ([Table II](#tII-mmr-18-05-4229){ref-type="table"}).

### Kaplan-Meier analysis

To identify potential biomarkers involved in ES progression, simultaneously with network degree \>10 (genes that directly interact with ≥10 other genes in the network) and \|log2Fold Change\|\>2 were screened. As a result, 22 genes were obtained ([Table III](#tIII-mmr-18-05-4229){ref-type="table"}) which contained 18 down- and 4 upregulated genes [Fig. 4](#f4-mmr-18-05-4229){ref-type="fig"} demonstrates their expression profiles in normal and ES samples. Kaplan-Meier analysis of the 22 genes based on the ES dataset from TCGA identified five genes, including *PYGM, MEF2C, TRIM63, BUB1B* and *RACGAP1*, which are significantly associated with ES OS ([Fig. 5](#f5-mmr-18-05-4229){ref-type="fig"}; P\<0.05) in the present study. Consistent with the differential expression analysis, upregulation of the three downregulated genes, *PYGM, MEF2C, TRIM63*, is associated with good ES prognosis, while, upregulation of the two upregulated genes, i.e., *BUB1B* and *RACGAP1*, are associated with poor ES prognosis ([Fig. 5](#f5-mmr-18-05-4229){ref-type="fig"}), which should provide valuable diagnosis and treatment biomarkers for ES.

### RT-qPCR

Expression differences of *PYGM, MEF2C, TRIM63, BUB1B* and *RACGAP1* between the ES cell lines A673 and normal cell lines MSC were investigated using RT-qPCR for their significant associations with OSCC\'s OS. Consistent with results from the microarray analysis, *PYGM, MEF2C* and *TRIM63* were downregulated, and *BUB1B* and *RACGAP1* were upregulated in the ES cell line compared with the normal cells ([Fig. 6](#f6-mmr-18-05-4229){ref-type="fig"}).

Discussion
==========

Ewing sarcoma is the second most frequent bone malignancy in children and adolescents ([@b26-mmr-18-05-4229]). Chemotherapy and surgery are currently the main therapeutic modalities for ES ([@b27-mmr-18-05-4229]). Despite aggressive therapy, the OS of ES patients is still dismal. The cure rate could be notably improved by the identification of molecular markers to aid the effective early diagnosis of malignancy and the prevention of tumor metastasis. In the present study, a meta-analysis of the transcriptomes of ES samples from three gene expression microarray datasets was performed, and 1,470 DEGs were identified, consisting of 984 up- and 486 downregulated genes. Using the DEGs, an ES disease network was constructed and six ES-associated disease clusters were obtained. Survival analysis identified five genes that were significantly associated with the survival rate of patients with ES.

GO term enrichment and clustering analysis were conducted for the 1,470 DEGs, and the GO terms were divided into five groups according to their biological roles in cell metabolism. The five groups are involved in the following physiological processes: Muscle contraction and morphogenesis, cell mitotic nuclear division and microtubule-based process, cell adhesion, heat generation process, and gluconeogenesis. Advanced malignancies that are often associated with bone metastasis can cause skeletal muscle weakness; the skeletal muscle quality is associated with muscle contraction and morphogenesis ([@b28-mmr-18-05-4229]). A previous study demonstrated that metastasis-induced transforming growth factor (TGF)-β release from bone contributes to muscle weakness by decreasing Ca^2+^-induced muscle force production ([@b29-mmr-18-05-4229]). Cell mitosis is closely associated with tumor progression and metastasis; there, microtubules have been a major target for anticancer drugs development ([@b30-mmr-18-05-4229]). Physiological thermogenesis is beneficial for damaging tumor tissues and improving the clinical outcomes of patients with cancer, while hyperthermia has a direct killing effect on tumor cells and can have an inhibitory effect on tumor metastasis ([@b31-mmr-18-05-4229]). Gluconeogenesis is a metabolic process whereby the body generates glucose from non-carbohydrate carbon source and provides energy for the growth and survival of cells ([@b32-mmr-18-05-4229]). Studies have suggested that gluconeogenesis could cause a metabolic stress and therefore disrupt the metabolic rewiring of cancer cells ([@b33-mmr-18-05-4229],[@b34-mmr-18-05-4229]). The five GO term groups identified in the present study, are all involved in cancer progression and metastasis, representing the typical ES progression-associated biological processes ([@b35-mmr-18-05-4229],[@b36-mmr-18-05-4229]).

As previously stated, based on the 1,470 DEGs, an ES disease network was constructed, and six disease clusters were ultimately identified. Several cancer-associated signaling pathways and metabolic processes were observed by enrichment analysis for the DEGs in each cluster. The cGMP-PKG signaling pathway was significantly enriched in the DEGs of clusters 1 and 3 and proved to be closely associated with tumor progression. Upregulated cGMP and its downstream protein kinase G (PKG) are known to inhibit the proliferation and induce the apoptosis of colon cancer cells, and activated intracellular cGMP-PKG pathway is known to enhance the degradation of β-catenin in SW480 colon cancer cells ([@b37-mmr-18-05-4229]--[@b39-mmr-18-05-4229]). Calcium signaling pathways were observed in clusters 1, 3 and 6; these signaling pathways serve a significant role in the cell apoptosis process ([@b35-mmr-18-05-4229]). Under pathological conditions, the Ca^2+^ level is markedly increased in many types of cells, resulting in the enhanced expression of pro-apoptotic factors ([@b40-mmr-18-05-4229]). Curcumin, a traditional Chinese medicine, may induce cell apoptosis through upregulating the Ca^2+^ level in lung cancer cells ([@b35-mmr-18-05-4229],[@b41-mmr-18-05-4229],[@b42-mmr-18-05-4229]). Certain disease-type markers, including Parkinson\'s disease (PD) associated genes \[VDAC1 ([@b43-mmr-18-05-4229]), VDAC3 ([@b44-mmr-18-05-4229])\], were observed in clusters 1 and 3. Many studies have demonstrated that the cancer incidence in patients with PD is significantly lower than in the patients without PD, but the detailed mechanism remains to be explored ([@b45-mmr-18-05-4229]). Many DEGs involved in the cell cycle process were in clusters 4 and 6. Cell proliferation is an essential mechanism for the growth, development and regeneration of eukaryotic organisms. Therefore, targeting the cell cycle process to regulate cell proliferation has been one of the most effective approaches to treat cancers ([@b46-mmr-18-05-4229]). Other signaling pathways or metabolic processes such as the mRNA surveillance pathway, the AGE-RAGE signaling pathway in diabetic complications, RNA degradation, cysteine and methionine metabolism and others were also observed in certain clusters. These signaling pathways or metabolic processes observed by enrichment analysis of the DEGs may participate in the progression and metastasis of ES and could also be considered potential molecular targets for early diagnosis and therapy ([@b35-mmr-18-05-4229],[@b36-mmr-18-05-4229]).

Survival analysis revealed that five DEGs were significantly associated with the survival rates of ES patients. *BUB1B* and *RACGAP1* were markedly upregulated in the ES samples. *BUB1B*, a member of the spindle assembly checkpoint protein family, has been associated with many types of cancer ([@b47-mmr-18-05-4229],[@b48-mmr-18-05-4229]). Upregulated expression of *BUB1B* enhanced the proliferation, migration, and invasion ability of prostate cancer cell lines ([@b48-mmr-18-05-4229]). *RACGAP1* is a component of the central spindle and essential for the induction of cytokinesis. Overexpressed *RACGAP1* was associated with poor disease-free and overall survival, and may act as an independent predictive marker for lymph node metastasis, recurrence and poor prognosis of colorectal cancer ([@b49-mmr-18-05-4229]--[@b51-mmr-18-05-4229]). The present results demonstrated that the expression of *BUB1B* and *RACGAP1* in ES samples is negatively associated with the survival rates of ES patients. In addition, the downregulated expression of *PYGM, MEF2C*, and *TRIM63* was also observed in the present study, with their expression being positively associated with the survival rates of ES patients. The present results suggest that *BUB1B, RACGAP1, PYGM, MEF2C*, and *TRIM63* may be considered potential markers for the prognosis of ES, but this needs to be investigated further.

In summary, the transcriptomes of ES samples from three independent gene expression chips was investigated and six disease clusters based on the 1,470 DEGs was constructed. Several cancer-associated signaling pathways, metabolic processes, or disease types were identified by the enrichment analysis, that could act as potential markers for early diagnosis and as targets for therapy. Survival analysis revealed that five DEGs were significantly associated with the survival rates of ES patients and could be considered predictive markers for the prognosis of ES, but this needs to be investigated further.

In the present study, a comprehensive analysis of three ES-associated microarray datasets was conducted and several KEGG pathways and GO term clusters that may be involved in ES progression were obtained. Additionally, five genes that are significantly associated with OS of patients with ES were identified, which may be helpful for ES early diagnosis and treatment, but this needs to be validated in future studies.
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![Differential expression analysis. (A) Heatmap of expression levels of the top 100 most significant DEGs. Horizontal and vertical axis represent genes and samples respectively and blue and red color represent low and high expression levels, respectively. Color bar at the top of the heatmap indicates sample type with red and blue indicating the ES and normal samples. (B) Volcano plot of the genes. X and Y axis is log2Fold Change and -log10-based adjusted P-value. Green and red dots are the down-regulated and up-regulated genes, respectively and black dots are the non-differential expressed genes. DEG, differentially expressed genes; ES, Ewing sarcoma.](MMR-18-05-4229-g00){#f1-mmr-18-05-4229}

![Functional enrichment analysis. (A) Significantly enriched signaling pathways of downregulated genes and (B) upregulated genes. Vertical axis is the gene number contained in the corresponding signaling pathway. The bar color indicates significance with the darker representing the more significant ones. (C) Crosstalk analysis of the BP terms of DEGs. Node and edge represent terms and interactions between two terms. Darker node color indicates more significance and larger node represents more genes contained in each term. Thicker edge indicates more overlapping genes between two terms. BP, biological processes; DEG, differentially expressed genes.](MMR-18-05-4229-g01){#f2-mmr-18-05-4229}

![Modular analysis of network. Node and edge represent genes and interactions among genes. Green and red color indicate down-regulation and up-regulation respectively.](MMR-18-05-4229-g02){#f3-mmr-18-05-4229}

![Heatmap of the 22 genes with network degree \>10 and \|log2Fold-Change\|\>2. Horizontal and vertical axis represent genes and samples, respectively and green and red color indicate low and high expression levels, respectively.](MMR-18-05-4229-g03){#f4-mmr-18-05-4229}

![Overall survival curves of the five genes significantly associated with ES prognosis obtained through the Kaplan-Meier analysis. Blue and red curve are samples with lower and higher expression levels than the median, respectively. Plus signs are censored values. The P-value was obtained through log-rank test. ES, Ewing sarcoma; HR represents hazard ratio.](MMR-18-05-4229-g04){#f5-mmr-18-05-4229}

![Validation of the data with RT-qPCR. The five genes identified in microarray data were validated by RT-qPCR. BUB1B, budding uninhibited by benzimidazoses1; MEF2C, myocyte-specific enhancer factor 2C; PYGM, glycogen phosphorylase; RACGAP, ras GTPase-activating protein 1, TRIM63, Tripartite Motif Containing 63. \*\*P\<0.01 and \*\*\*P\<0.001 A673 vs. MSC group.](MMR-18-05-4229-g05){#f6-mmr-18-05-4229}

###### 

Microarray experiments used for meta-analysis.

                                         Characteristic                                        
  ---------- --------------------------- --------------------- ---------------------- -------- ----------
  GSE34620   117/117                     Ewing sarcoma (117)   NA                     GPL570   22327514
  GSE17618   44/55 (exclude cell line)   Ewing sarcoma (44)    NA                     GPL570   22084725
  GSE17674   62/62                       Ewing sarcoma (44)    Skeletal muscle (18)   GPL570   22084725

ES, Ewing sarcoma; GEO, gene expression omnibus.

###### 

Significantly enriched KEGG pathways of the six network modules.

  **A, Module 1**                                                                            
  ------------------------------------------------------ ---------------- ------------------ ------------------
  Parkinson\'s disease                                   hsa05012         6.01×10^−5^        8.51×10^−4^
  cGMP-PKG signaling pathway                             hsa04022         9.64×10^−5^        8.51×10^−4^
  RNA transport                                          hsa03013         1.05×10^−4^        8.51×10^−4^
  Calcium signaling pathway                              hsa04020         1.20×10^−4^        8.51×10^−4^
  Huntington\'s disease                                  hsa05016         1.47×10^−4^        8.51×10^−4^
  HTLV-I infection                                       hsa05166         3.44×10^−4^        1.66×10^−3^
  Ribosome biogenesis in eukaryotes                      hsa03008         1.06×10^−3^        4.38×10^−3^
  Ribosome                                               hsa03010         2.47×10^−3^        8.96×10^−3^
  Viral carcinogenesis                                   hsa05203         5.30×10^−3^        1.71×10^−2^
                                                                                             
  **B, Module 2**                                                                            
                                                                                             
  **Spliceosome**                                        **hsa03040**     **3.82×10^−19^**   **6.87×10^−18^**
                                                                                             
  African trypanosomiasis                                hsa05143         1.35×10^−2^        6.87×10^−2^
  Malaria                                                hsa05144         1.87×10^−2^        6.87×10^−2^
  Pathogenic Escherichia coli infection                  hsa05130         2.09×10^−2^        6.87×10^−2^
  RNA degradation                                        hsa03018         2.90×10^−2^        6.87×10^−2^
  Gap junction                                           hsa04540         3.30×10^−2^        6.87×10^−2^
  mRNA surveillance pathway                              hsa03015         3.45×10^−2^        6.87×10^−2^
  NF-kappa B signaling pathway                           hsa04064         3.49×10^−2^        6.87×10^−2^
  AGE-RAGE signaling pathway in diabetic complications   hsa04933         3.78×10^−2^        6.87×10^−2^
  TNF signaling pathway                                  hsa04668         4.11×10^−2^        6.87×10^−2^
  Leukocyte transendothelial migration                   hsa04670         4.40×10^−2^        6.87×10^−2^
                                                                                             
  **C, Module 3**                                                                            
                                                                                             
  **RNA degradation**                                    **hsa03018**     **9.77×10^−3^**    **2.76×10^−2^**
                                                                                             
  Parkinson\'s disease                                   hsa05012         1.79×10^−2^        2.76×10^−2^
  Wnt signaling pathway                                  hsa04310         1.80×10^−2^        2.76×10^−2^
  cGMP-PKG signaling pathway                             hsa04022         2.09×10^−2^        2.76×10^−2^
  Influenza A                                            hsa05164         2.21×10^−2^        2.76×10^−2^
  Calcium signaling pathway                              hsa04020         2.26×10^−2^        2.76×10^−2^
  Huntington\'s disease                                  hsa05016         2.42×10^−2^        2.76×10^−2^
  HTLV-I infection                                       hsa05166         3.23×10^−2^        3.23×10^−2^
                                                                                             
  **D, Module 4**                                                                            
                                                                                             
  **Cell cycle**                                         **hsa04110**     **7.15×10^−8^**    **2.29×10^−6^**
                                                                                             
  DNA replication                                        hsa03030         2.48×10^−7^        3.96×10^−6^
  Pathogenic Escherichia coli infection                  hsa05130         8.33×10^−7^        8.88×10^−6^
  Gap junction                                           hsa04540         3.89×10^−4^        3.11×10^−3^
  Phagosome                                              hsa04145         1.17×10^−3^        7.51×10^−3^
  MicroRNAs in cancer                                    hsa05206         4.21×10^−3^        2.25×10^−2^
                                                                                             
  **E, Module 5**                                                                            
                                                                                             
  **Cysteine and methionine metabolism**                 **hsa00270**     **6.92×10^−3^**    **2.95×10^−2^**
                                                                                             
  Pathogenic Escherichia coli infection                  hsa05130         8.42×10^−3^        2.95×10^−2^
  Gap junction                                           hsa04540         1.34×10^−2^        3.12×10^−2^
  Apoptosis                                              hsa04210         2.11×10^−2^        3.26×10^−2^
  Phagosome                                              hsa04145         2.33×10^−2^        3.26×10^−2^
                                                                                             
  **F, Module 6**                                                                            
                                                                                             
  **Pathway**                                            **Pathway ID**   **P-value**        **FDR**
                                                                                             
  Oocyte meiosis                                         hsa04114         3.67×10^−6^        2.25×10^−5^
  Cell cycle                                             hsa04110         3.75×10^−6^        2.25×10^−5^
  HTLV-I infection                                       hsa05166         3.28×10^−5^        1.31×10^−4^
  Ubiquitin mediated proteolysis                         hsa04120         5.36×10^−4^        9.19×10^−4^
  Thyroid cancer                                         hsa05216         7.52×10^−3^        1.00×10^−2^
  Progesterone-mediated oocyte maturation                hsa04914         2.46×10^−2^        2.95×10^−2^
  Calcium signaling pathway                              hsa04020         4.46×10^−2^        4.86×10^−2^
  Pathways in cancer                                     hsa05200         9.57×10^−2^        9.57×10^−2^

FDR, false discovery data; KEGG, Kyoto Encyclopedia of Genes and Genome.

###### 

A total of 22 genes with degree\>10 and \|log2(Fold-change)\|\>2.

  Gene symbol   Full name                                                   logFC   Degree
  ------------- ----------------------------------------------------------- ------- --------
  ACTA1         Actin, α 1, skeletal muscle                                 −5.18   31
  TNNT1         Troponin T1, slow skeletal type                             −4.19   15
  PYGM          Glycogen phosphorylase, muscle associated                   −4.02   15
  MYBPC2        Myosin binding protein C, fast type                         −3.91   13
  NEB           Nebulin                                                     −3.31   14
  FHL1          Four and A half LIM domains 1                               −3.23   11
  TCAP          Titin-Cap                                                   −3.13   11
  TRIM63        Tripartite motif containing 63                              −3.01   27
  RYR1          Ryanodine receptor 1                                        −2.94   10
  TTN           Titin                                                       −2.90   36
  ACTN2         Actinin α 2                                                 −2.86   16
  SGCG          Sarcoglycan γ                                               −2.68   14
  CRYAB         Crystallin α B                                              −2.59   14
  EEF1A2        Eukaryotic translation elongation factor 1 α 2              −2.57   11
  ENO3          Enolase 3                                                   −2.13   11
  MEF2C         Myocyte enhancer factor 2C                                  −2.06   10
  PRKCQ         Protein kinase C θ                                          −2.06   19
  FLNC          Filamin C                                                   −2.02   16
  RACGAP1       Ras GTPase activating protein 1                             2.15    10
  BUB1B         BUB1 mitotic checkpoint serine/threonine kinase B           2.20    12
  EZH2          Enhancer of zeste 2 polycomb repressive complex 2 subunit   2.61    31
  CCND1         Cyclin D1                                                   2.75    16

[^1]: Contributed equally
